FDA aims for greater use of remote assessments for low-risk facilities
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyComplianceGenericsPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesRegulatory NewsJoanne S. EglovitchAudit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyComplianceGenericsPharmaceuticalsRegulatory Intelligence/PolicyUnited States